A proper MS diagnosis can only be made after obtaining imaging from the entire brain and understanding the clinical context.
Researchers report 2 cases of a severe B-cell-mediated CNS disease after treatment with alemtuzumab in patients with multiple sclerosis.
More structured MRI reports may aid in the diagnosis of multiple sclerosis.
It is not clear whether CSF CD27 could provide novel or simply complementary prognostic value in clinically isolated syndrome.
Low levels of neonatal vitamin D may be linked with risk of developing multiple sclerosis.
Previous MRI studies focused on gray matter changes only.
The authors aimed to identify confirmed disability improvement (CDI), which reflects a clinically meaningful change in EDSS score.
Researchers still recommend that patients with MS engage in physical activity for cardiovascular benefits.
Researchers believe that the drug may help prevent MS, since there was a 96% reduction in harmful clusters of B cells.
Notably, patients who had documented psychotic and psychiatric disorders were more likely to be diagnosed with a demyelinating disease.
Over 90% of participants achieved NEDA-3 after being transitioned to dimethyl-fumarate from natalizumab.
Neurology Advisor Articles
- No Difference in Neurodevelopment in Children Conceived by Assisted Reproduction
- Case Report: Treatment With Alemtuzumab May Prompt Severe CNS Disease
- Treating Pain in Depression May Help Improve Cognition
- The Handoff: Your Week in Neurology News - 1/19/17
- FDA Warns of Implantable Infusion Pumps in MRI